Proactive Investors - Run By Investors For Investors

MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering
Cell being injected
Flow Electroporation is used in gene editing and allows almost any molecule to be delivered into a cell

MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform.

The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering.

WATCH: Major announcements for MaxCyte

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

Doug Doerfler, president and chief executive of MaxCyte, said Kite would be utilising the firm’s platform to enable gene-editing technologies for the research and development of new therapeutics.

The deal follows a commercial license agreement signed last week between MaxCyte and gene-based medicine maker CRISPR Therapeutics in a move to advance the development of anti-cancer treatments.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
A stomach adenocarcinoma
Wed
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use